2seventy bio, Inc. (TSVT) announced that it will discontinue enrollment in its ongoing phase III KarMMa-9 study. The study is evaluating Abecma (idecabtagene vicleucel; ide-cel) with Revlimid (lenalidomide) maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have a suboptimal response to autologous stem cell transplant. Shares of TSVT were down 9.4% on the news. Year to date, TSVT's shares have gained 1.2% against the industry's decline of 3.5%. Ima ...